@prefix prodottidellaricerca: . @prefix istituto: . @prefix prodotto: . istituto:CDS045 prodottidellaricerca:prodotto prodotto:ID30198 . @prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . unitaDiPersonaleInterno:MATRICOLA39052 pubblicazioni:autoreCNRDi prodotto:ID30198 . @prefix modulo: . modulo:ID2507 prodottidellaricerca:prodotto prodotto:ID30198 . @prefix rdf: . @prefix retescientifica: . prodotto:ID30198 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1101 . @prefix rdfs: . prodotto:ID30198 rdfs:label "Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID30198 pubblicazioni:anno "2005-01-01T00:00:00+01:00"^^xsd:gYear ; pubblicazioni:doi "10.1210/jc.2004-2460"^^xsd:string . @prefix skos: . prodotto:ID30198 skos:altLabel "
Mari A.; Sallas W. M.; He Y. L.; Watson C.; Ligueros-Saylan M.; Dunning B. E.; Deacon C. F.; Holst J. J.; Foley J. E. (2005)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
in The Journal of clinical endocrinology and metabolism
"^^rdf:HTML ; pubblicazioni:autori "Mari A.; Sallas W. M.; He Y. L.; Watson C.; Ligueros-Saylan M.; Dunning B. E.; Deacon C. F.; Holst J. J.; Foley J. E."^^xsd:string ; pubblicazioni:paginaInizio "4888"^^xsd:string ; pubblicazioni:paginaFine "4894"^^xsd:string ; pubblicazioni:numeroVolume "90"^^xsd:string . @prefix ns11: . prodotto:ID30198 pubblicazioni:rivista ns11:ID294077 ; pubblicazioni:numeroFascicolo "8"^^xsd:string ; skos:note "ISI Web of Science (WOS)"^^xsd:string ; pubblicazioni:affiliazioni "1: National Research Center, Institute of Biomedical Engineering, Padova, Italy /\n2, 5, 9: Novartis Pharmaceuticals Corp., East Hanover, New Jersey 07936 /\n3, 4: Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 /\n6: PharmaWrite, LLC (B.E.D.), Princeton, NJ 08540 /\n7, 8: Panum Institute, University of Copenhagen, Copenhagen, Denmark"^^xsd:string ; pubblicazioni:titolo "Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes"^^xsd:string ; prodottidellaricerca:abstract "vildagliptin,\nincreases levels of intact glucagon-like peptide-1 (GLP-1) and\nimproves glycemic control in patients with type 2 diabetes. Although\nGLP-1 is known to stimulate insulin secretion, vildagliptin does not\naffect plasma insulin levels in diabetic patients, suggesting that more\nsophisticated measures are necessary to ascertain the influence of\nvildagliptin on ?-cell function.\nMethods: This study examined the effects of 28-d treatment with\nvildagliptin (100 mg, twice daily; n ? 9) vs. placebo (n ? 11) on ?-cell\nfunction in diabetic patients using a mathematical model that describes\nthe insulin secretory rate as a function of glucose levels (?-cell\ndose response), the change in glucose with time (derivative component),\nand a potentiation factor, which is a function of time and may\nreflect the actions of nonglucose secretagogues and other factors.\nResults: Vildagliptin significantly increased the insulin secretory\nrate at 7 mmol/liter glucose (secretory tone), calculated from the dose\nresponse; the difference in least squares mean (?LSM) was 101 ? 51\npmol?min?1?m?2 (P?0.002). The slope of the ?-cell dose response, the\nderivative component, and the potentiation factor were not affected.\nVildagliptin also significantly decreased mean prandial glucose\n(?LSM, ?1.2 ? 0.4 mmol/liter; P ? 0.01) and glucagon (?LSM,\n?10.7 ? 4.8 ng/liter; P ? 0.03) levels and increased plasma levels of\nintact GLP-1 (?LSM, ?10.8 ? 1.6 pmol/liter; P ? 0.0001) and gastric\ninhibitory polypeptide (?LSM, ?43.4 ? 9.4 pmol/liter; P ? 0.0001)\nrelative to placebo.\nConclusion: Vildagliptin is an incretin degradation inhibitor that\nimproves ?-cell function in diabetic patients by increasing the insulin\nsecretory tone"@en ; prodottidellaricerca:prodottoDi istituto:CDS045 , modulo:ID2507 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA39052 . ns11:ID294077 pubblicazioni:rivistaDi prodotto:ID30198 .